newsfilter
← Latest News
GlobeNewswire·

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, May 06,